C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
Key Highlights
- ➤C4T’s DEL identified attractive hits against high-value targets within four months
- ➤C4T validated DEL by identifying known and novel molecular glue degrader hits for VAV1
- ➤C4T will not advance VAV1 without a partner
- ➤C4T remains focused on advancing cemsidomide through clinical development
Expert Statements
Scott Boyle, Chief business officer of C4 Therapeutics
“Our new DEL capability captures both our strong track record of investing in cereblon and driving innovation across targeted protein degradation science to create a differentiated engine for generating new drug discovery opportunities.”
Scott Boyle, Chief business officer of C4 Therapeutics
“To date, this new technology has shown it can deliver attractive hits against high-value targets within four months and further enhances the speed and precision of our discovery efforts.”
Scott Boyle, Chief business officer of C4 Therapeutics
“We are eager to push the boundaries of this library and our rapid screening process with diverse and undruggable targets both for our own internal pipeline and alongside future partners.”
WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today highlighted its novel DNA-encoded library (DEL) that leverages C4T’s large library of cereblon-binding ligands and screening capabilities in a presentation at the 9(th) Annual Targeted Protein Degradation Summit in Boston titled “Target-First Discovery of Molecular Glue Degraders Using DNA-Encoded Libraries.”
“Our new DEL capability captures both our strong track record of investing in cereblon and driving innovation across targeted protein degradation science to create a differentiated engine for generating new drug discovery opportunities,” said Scott Boyle, chief business officer of C4 Therapeutics. “To date, this new technology has shown it can deliver attractive hits against high-value targets within four months and further enhances the speed and precision of our discovery efforts. We are eager to push the boundaries of this library and our rapid screening process with diverse and undruggable targets both for our own internal pipeline and alongside future partners.”
Get started
Create a free account to read the full story.